Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 17, 2016

Primary Completion Date

February 10, 2018

Study Completion Date

March 17, 2026

Conditions
Metastatic MelanomaRecurrent Cutaneous MelanomaStage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
DRUG

Ibrutinib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacogenomic Study

Correlative studies

OTHER

Pharmacological Study

Correlative studies

Trial Locations (13)

22908

University of Virginia Cancer Center, Charlottesville

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

27710

Duke University Medical Center, Durham

33612

Moffitt Cancer Center, Tampa

40536

University of Kentucky/Markey Cancer Center, Lexington

43210

Ohio State University Comprehensive Cancer Center, Columbus

44106

Case Western Reserve University, Cleveland

53792

University of Wisconsin Carbone Cancer Center - University Hospital, Madison

63110

Washington University School of Medicine, St Louis

80045

UCHealth University of Colorado Hospital, Aurora

90033

Los Angeles General Medical Center, Los Angeles

USC / Norris Comprehensive Cancer Center, Los Angeles

95817

University of California Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH